The Experts below are selected from a list of 24 Experts worldwide ranked by ideXlab platform
G G Skellern - One of the best experts on this subject based on the ideXlab platform.
-
Micellar electrokinetic and high-performance liquid chromatographic determination of potential manufacturing impurities in pholcodine.
Journal of chromatography. A, 2000Co-Authors: O M Denk, D G Watson, G G SkellernAbstract:Quantitative high-performance liquid chromatographic (HPLC) and micellar electrokinetic chromatographic (MEKC) methods have been developed for the determination of four structurally related potential manufacturing impurities, including morphine, of the Opiate Derivative pholcodine. Pholcodine and the four impurities were separated by MEKC in less than 14 min using a 70 cm x 75 microm I.D. uncoated fused-silica capillary (25 kV at 30 degrees C) and a running buffer consisting of 10% acetonitrile (v/v) in 20 mM borate-phosphate buffer pH 8.0 containing 40 mM sodium dodecyl sulphate (SDS). The MEKC method was compared to a HPLC method using a 5 microm Luna phenyl-hexyl column (150 x 4.6 mm I.D.) eluted with a mobile phase consisting of a mixture of 10% (v/v) acetonitrile, 7% (v/v) tetrahydrofuran in 20 mM phosphate buffer pH 8.0. Both methods were fully validated and a comparison was made regarding selectivity, linearity, precision, robustness and limits of detection and quantitation. The presence of the impurities in different samples of pholcodine drug substance was investigated using both methods.
-
Micellar electrokinetic and high-performance liquid chromatographic determination of potential manufacturing impurities in pholcodine.
Journal of Chromatography A, 2000Co-Authors: O M Denk, D G Watson, G G SkellernAbstract:Abstract Quantitative high-performance liquid chromatographic (HPLC) and micellar electrokinetic chromatographic (MEKC) methods have been developed for the determination of four structurally related potential manufacturing impurities, including morphine, of the Opiate Derivative pholcodine. Pholcodine and the four impurities were separated by MEKC in less than 14 min using a 70 cm×75 μm I.D. uncoated fused-silica capillary (25 kV at 30°C) and a running buffer consisting of 10% acetonitrile (v/v) in 20 mM borate–phosphate buffer pH 8.0 containing 40 mM sodium dodecyl sulphate (SDS). The MEKC method was compared to a HPLC method using a 5 μm Luna phenyl–hexyl column (150×4.6 mm I.D.) eluted with a mobile phase consisting of a mixture of 10% (v/v) acetonitrile, 7% (v/v) tetrahydrofuran in 20 mM phosphate buffer pH 8.0. Both methods were fully validated and a comparison was made regarding selectivity, linearity, precision, robustness and limits of detection and quantitation. The presence of the impurities in different samples of pholcodine drug substance was investigated using both methods.
O M Denk - One of the best experts on this subject based on the ideXlab platform.
-
Micellar electrokinetic and high-performance liquid chromatographic determination of potential manufacturing impurities in pholcodine.
Journal of chromatography. A, 2000Co-Authors: O M Denk, D G Watson, G G SkellernAbstract:Quantitative high-performance liquid chromatographic (HPLC) and micellar electrokinetic chromatographic (MEKC) methods have been developed for the determination of four structurally related potential manufacturing impurities, including morphine, of the Opiate Derivative pholcodine. Pholcodine and the four impurities were separated by MEKC in less than 14 min using a 70 cm x 75 microm I.D. uncoated fused-silica capillary (25 kV at 30 degrees C) and a running buffer consisting of 10% acetonitrile (v/v) in 20 mM borate-phosphate buffer pH 8.0 containing 40 mM sodium dodecyl sulphate (SDS). The MEKC method was compared to a HPLC method using a 5 microm Luna phenyl-hexyl column (150 x 4.6 mm I.D.) eluted with a mobile phase consisting of a mixture of 10% (v/v) acetonitrile, 7% (v/v) tetrahydrofuran in 20 mM phosphate buffer pH 8.0. Both methods were fully validated and a comparison was made regarding selectivity, linearity, precision, robustness and limits of detection and quantitation. The presence of the impurities in different samples of pholcodine drug substance was investigated using both methods.
-
Micellar electrokinetic and high-performance liquid chromatographic determination of potential manufacturing impurities in pholcodine.
Journal of Chromatography A, 2000Co-Authors: O M Denk, D G Watson, G G SkellernAbstract:Abstract Quantitative high-performance liquid chromatographic (HPLC) and micellar electrokinetic chromatographic (MEKC) methods have been developed for the determination of four structurally related potential manufacturing impurities, including morphine, of the Opiate Derivative pholcodine. Pholcodine and the four impurities were separated by MEKC in less than 14 min using a 70 cm×75 μm I.D. uncoated fused-silica capillary (25 kV at 30°C) and a running buffer consisting of 10% acetonitrile (v/v) in 20 mM borate–phosphate buffer pH 8.0 containing 40 mM sodium dodecyl sulphate (SDS). The MEKC method was compared to a HPLC method using a 5 μm Luna phenyl–hexyl column (150×4.6 mm I.D.) eluted with a mobile phase consisting of a mixture of 10% (v/v) acetonitrile, 7% (v/v) tetrahydrofuran in 20 mM phosphate buffer pH 8.0. Both methods were fully validated and a comparison was made regarding selectivity, linearity, precision, robustness and limits of detection and quantitation. The presence of the impurities in different samples of pholcodine drug substance was investigated using both methods.
Michel Auguet - One of the best experts on this subject based on the ideXlab platform.
-
simultaneous separate or staggered therapeutic use in time of at least one botulinum neurotoxin and at least one Opiate Derivative
2007Co-Authors: Michel Auguet, Christine Favre, Pierreetienne Chabrier De LassauniereAbstract:Product comprising: - a botulinum neurotoxin, and - an Opiate Derivative or salt thereof for use in the treatment of inflammatory pain, wherein the botulinum toxin and derivadoopiaceo or its salt is administered at doses sub-active.
-
therapeutic use simultaneous separate or spread over time of at least one botulinum neurotoxin and at least one Opiate Derivative
2006Co-Authors: Michel Auguet, Christine Favre, De Lassauniere Pierreetienne ChabrierAbstract:The present invention relates to a composition comprising: - at least one botulinum neurotoxin, and- at least one Opiate or sel.L'invention also relates to a product comprising at least one botulinum neurotoxin and at least one Opiate Derivative or Derivative its salt as combination product for a therapeutic use simultaneously, separately or spread over time in the treatment or prevention of pain and neuromuscular disorders.
D G Watson - One of the best experts on this subject based on the ideXlab platform.
-
Micellar electrokinetic and high-performance liquid chromatographic determination of potential manufacturing impurities in pholcodine.
Journal of chromatography. A, 2000Co-Authors: O M Denk, D G Watson, G G SkellernAbstract:Quantitative high-performance liquid chromatographic (HPLC) and micellar electrokinetic chromatographic (MEKC) methods have been developed for the determination of four structurally related potential manufacturing impurities, including morphine, of the Opiate Derivative pholcodine. Pholcodine and the four impurities were separated by MEKC in less than 14 min using a 70 cm x 75 microm I.D. uncoated fused-silica capillary (25 kV at 30 degrees C) and a running buffer consisting of 10% acetonitrile (v/v) in 20 mM borate-phosphate buffer pH 8.0 containing 40 mM sodium dodecyl sulphate (SDS). The MEKC method was compared to a HPLC method using a 5 microm Luna phenyl-hexyl column (150 x 4.6 mm I.D.) eluted with a mobile phase consisting of a mixture of 10% (v/v) acetonitrile, 7% (v/v) tetrahydrofuran in 20 mM phosphate buffer pH 8.0. Both methods were fully validated and a comparison was made regarding selectivity, linearity, precision, robustness and limits of detection and quantitation. The presence of the impurities in different samples of pholcodine drug substance was investigated using both methods.
-
Micellar electrokinetic and high-performance liquid chromatographic determination of potential manufacturing impurities in pholcodine.
Journal of Chromatography A, 2000Co-Authors: O M Denk, D G Watson, G G SkellernAbstract:Abstract Quantitative high-performance liquid chromatographic (HPLC) and micellar electrokinetic chromatographic (MEKC) methods have been developed for the determination of four structurally related potential manufacturing impurities, including morphine, of the Opiate Derivative pholcodine. Pholcodine and the four impurities were separated by MEKC in less than 14 min using a 70 cm×75 μm I.D. uncoated fused-silica capillary (25 kV at 30°C) and a running buffer consisting of 10% acetonitrile (v/v) in 20 mM borate–phosphate buffer pH 8.0 containing 40 mM sodium dodecyl sulphate (SDS). The MEKC method was compared to a HPLC method using a 5 μm Luna phenyl–hexyl column (150×4.6 mm I.D.) eluted with a mobile phase consisting of a mixture of 10% (v/v) acetonitrile, 7% (v/v) tetrahydrofuran in 20 mM phosphate buffer pH 8.0. Both methods were fully validated and a comparison was made regarding selectivity, linearity, precision, robustness and limits of detection and quantitation. The presence of the impurities in different samples of pholcodine drug substance was investigated using both methods.
De Lassauniere Pierreetienne Chabrier - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic use simultaneous separate or spread over time of at least one botulinum neurotoxin and at least one Opiate Derivative
2006Co-Authors: Michel Auguet, Christine Favre, De Lassauniere Pierreetienne ChabrierAbstract:The present invention relates to a composition comprising: - at least one botulinum neurotoxin, and- at least one Opiate or sel.L'invention also relates to a product comprising at least one botulinum neurotoxin and at least one Opiate Derivative or Derivative its salt as combination product for a therapeutic use simultaneously, separately or spread over time in the treatment or prevention of pain and neuromuscular disorders.